Trial Profile
A Randomized Phase II Trial Comparing Bendamustine and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Melphalan (Primary)
- Indications Myeloma
- Focus Therapeutic Use
- Acronyms BEB-2
- Sponsors Mundipharma Medical Company
- 20 Apr 2022 Primary endpoint (Complete Remission rate) has been met according to the results published in the Bone Marrow Transplantation
- 20 Apr 2022 Results published in the Bone Marrow Transplantation
- 24 Jul 2020 Status changed from active, no longer recruiting to completed.